Results 61 to 70 of about 76,925 (188)
Psoriatic Arthritis Registries
The Journal of Rheumatology Supplement, 2015 The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics ...
Sarzi-Puttini, Piercarlo +4 more
openaire +3 more sources
99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients : a biodistribution and dosimetry study [PDF]
, 2016 Background: Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis.
Bacher, Klaus +9 more
core +2 more sources
Viewpoint on handling anti-TNF failure in psoriasis [PDF]
, 2013 An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core +1 more source
Psoriatic arthritis – new perspectives [PDF]
Archives of Medical Science, 2019 Psoriatic arthritis (PsA) is a seronegative arthropathy with many clinical manifestations, and it may affect nearly a half of patients with psoriasis. PsA should be diagnosed as early as possible to slow down joint damage and progression of disability.
Przemysław Krakowski +6 more
openaire +3 more sources
BMC Musculoskeletal Disorders, 2019 Background Active foot disease persists in a high proportion of people with psoriatic arthritis despite the availability of pharmacological and non-pharmacological interventions to modify the course of the disease.
Kate Carter +3 more
doaj +1 more source
Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]
, 2018 Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M +2 more
core +1 more source
CLINICAL OUTCOME MEASURES OF PSORIASIS
Reumatismo, 2011 Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations.
E. Berardesca, C. Bonifati
doaj +1 more source
Seronegative spondyloarthropathies : a review : part I: classification and differential diagnosis [PDF]
, 1993 The seronegative spondyloarthropathies comprise a group of non-rheumatoid disorders with similar clinical, laboratory and genetic features. Recognition of new clinical features has supported the notion that they all form part of a clinical spectrum ...
Borg, Andrew A. +2 more
core
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study [PDF]
, 2017 Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods. Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2,
Delicha, Eumorphia-Maria +9 more
core +2 more sources
Early Psoriatic Arthritis [PDF]
Rheumatic Disease Clinics of North America, 2015 Skin psoriasis is a major risk factor for the development of psoriatic arthritis. Recent studies have shown that delayed diagnosis is associated with long-term adverse outcomes. Screening questionnaires have revealed a potential burden of undiagnosed disease. Lifestyle factors and genetic and soluble biomarkers have come under scrutiny as risk factors.
openaire +2 more sources